Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma.

@article{Pollom2015ConcurrentVA,
  title={Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma.},
  author={Erqi L Pollom and Timothy T. Bui and A L S Chang and Alexander Dimitrios Colevas and Wendy Y Hara},
  journal={JAMA dermatology},
  year={2015},
  volume={151 9},
  pages={998-1001}
}
IMPORTANCE Vismodegib is a targeted agent recently approved for treating patients who develop recurrent or locally advanced basal cell carcinoma (BCC), and will inevitably be integrated into existing therapy for advanced BCC as it becomes increasingly used. Improved understanding of how vismodegib interacts with other treatment modalities, including radiotherapy, would help optimize multidisciplinary therapy and clinical outcomes. OBSERVATIONS We report 2 cases of recurrent, advanced BCC… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 15 references

Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma. https://www .clinicaltrials.gov/ct2/show/NCT01835626

  • ClinicalTrials.gov. NCT
  • Accessed February
  • 2015

Similar Papers

Loading similar papers…